Related Experiment Video
Updated: Jun 12, 2026
04:49
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
Published on: December 12, 2019
Toward end-to-end continuous biopharmaceutical manufacturing: Current advances and prospects
Seonbong Lee1, Taehyeon Kim2, Jimin Kang1
1Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea.
New Biotechnology
|June 10, 2026
Summary
End-to-end continuous biopharmaceutical manufacturing requires integrating upstream and downstream processes. Overcoming interface mismatches is key for sustained, high-quality production with minimal pooling.
Area of Science:
- Biopharmaceutical Manufacturing
- Chemical Engineering
- Process Intensification
Background:
- Continuous manufacturing offers process intensification beyond individual unit operations.
- End-to-end continuity integrates upstream and downstream processing for long-duration operation with minimal pooling.
Purpose of the Study:
- To review progress in end-to-end continuous biopharmaceutical manufacturing.
- To frame continuity as a system-level integration and interface-engineering challenge.
- To identify barriers and solutions for achieving practical end-to-end continuity.
Main Methods:
- Systematic review of recent advancements in upstream and downstream bioprocessing.
- Analysis of integration case studies focusing on interface challenges.
- Discussion of enabling technologies like PAT and digital twins.
Main Results:
- Perfusion upstream processes enable high cell density but require strict parameter control.
- Continuous downstream operations (capture, polishing, viral clearance) are increasingly feasible.
- Interface mismatches between upstream and downstream operations are the primary barrier, necessitating synchronization and conditioning.
Conclusions:
- Achieving end-to-end continuity relies on robust interface engineering and platform integration.
- Addressing cyclic dynamics and feed variability is crucial for long-duration robustness.
- Coordinated advances in technology and validation are essential for practical implementation.
Keywords:
Continuous biomanufacturingDigital twinInterface engineeringProcess analytical technologyProcess integrationResidence-time distributionUltra scale-downMore Related Videos
Related Concept Videos
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:14Batch vs Continuous Culture
Fermentation is a foundational biotechnological process used to produce pharmaceuticals, biofuels, enzymes, and food additives. Among industrial strategies, batch and continuous fermentation are the two most widely applied. Although both rely on microbial conversion of substrates into desired products, they differ markedly in operation, productivity, and suitability for specific applications.Batch fermentation occurs in a closed system in which nutrient media and inoculum are added at the...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...